BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Qu FJ, Wu S, Kong Y. Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report. World J Gastrointest Oncol 2023; 15(5): 902-910 [PMID: 37275454 DOI: 10.4251/wjgo.v15.i5.902]
URL: https://www.wjgnet.com/1948-5204/full/v15/i5/902.htm
Number Citing Articles
1
D. Xu, S. Zeng, W. Qiu, G. Wang, Z. Qin, Y. Liu, S. Zhou, Z. Zhang, W. Chang, Q. Feng, J. Xu. Fruquintinib in refractory metastatic colorectal cancer: a multicenter real-world studyESMO Open 2024; 9(11): 103702 doi: 10.1016/j.esmoop.2024.103702
2
Antineoplastics/folinic-acidReactions Weekly 2023; 1961(1): 64 doi: 10.1007/s40278-023-41321-y
3
Majid Moradian, Batoul Makiabadi, Mohammad Zakarianezhad, Abdolreza Faramarzi. Evaluation of Drug Delivery Systems Based on Host–guest Interactions Between Pure/Metal‐doped BN Nanotubes with Oteracil and Potassium Oteracil Anticancer DrugsChemistrySelect 2025; 10(4) doi: 10.1002/slct.202403589
4
Linfeng Liu, Dengzhuo Chen, Liang Wen, Yongli Ma, Jinghui Li, Guosheng Zhang, Hongkai Hu, Chengzhi Huang, Xueqing Yao. Efficacy and safety of fruquintinib combined with PD-1 inhibitors in the treatment of refractory metastatic colorectal cancer: a systematic review and meta-analysisExpert Review of Anticancer Therapy 2025; : 1 doi: 10.1080/14737140.2025.2474736